TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19618230

Group type: EXPERIMENTAL
Intervention: High Meat Group (HM, n = 48) receiving commercial baby jars with a meat content of 12% by weight
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low Meat Group (LM, n = 49) receiving meals with meat 8% by weight
Number of subjects: 97
Study: 18356842

Group type: EXPERIMENTAL
Intervention: 3 g/day CLA (50:50 cis-9, trans-11:trans-10, cis-12) and 3 g/day n-3 LC-PUFA
Number of subjects: 59

Group type: COMPARATOR
Intervention: 6 g/day control fat
Number of subjects: 59
Study: 15823638

Group type: EXPERIMENTAL
Intervention: PTr (combined strength and endurance exercises) four times per week, twice supervised and twice at home, during 26 weeks.
Number of subjects: 61
Study: 12091192

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 12666963

Group type: EXPERIMENTAL
Intervention: Scaling and root planning (one session of one hour)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel (ELYZOL DENTAL GEL) applied on day 0 and day 7
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Scaling adjunctive to metronidazole 25%
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 14
Study: 8691500

Group type: EXPERIMENTAL
Intervention: HMO intervention (mailed personal letters and newsletter articles)
Number of subjects: 574
Study: 1797462

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (LNg 20)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Copper T 380Ag IUD
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both IUDs
Number of subjects: 5
Study: 6689038

Group type: EXPERIMENTAL
Intervention: Calcitriol administration (0.75 micrograms every 6 hr)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (low Ca diet, 4.2 +/- 0.9 mmoles Ca/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcitriol administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 29869037

Group type: EXPERIMENTAL
Intervention: HLA6/6-matched haplo‐HSCT
Number of subjects: 27
Study: 29017069

Group type: EXPERIMENTAL
Intervention: Comprehensive self-control training (CSCT) program for 8 weeks with a 4-month follow-up consolidation program.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group received only pre-post-and-follow-up measurements.
Number of subjects: 74
Study: 26658121

Group type: EXPERIMENTAL
Intervention: Novel teat (NT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional teat (CT)
Number of subjects: 0
Study: 25052080

Group type: EXPERIMENTAL
Intervention: Questionnaires with pictograms
Number of subjects: 76

Group type: COMPARATOR
Intervention: Questionnaires without pictograms
Number of subjects: 76
Study: 22791904

Group type: EXPERIMENTAL
Intervention: Posiphen treatment for 10 days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study: 20555173

Group type: EXPERIMENTAL
Intervention: Computer-generated stretching program (n=22)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hard copy version of stretches (n=23)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 17852789

Group type: EXPERIMENTAL
Intervention: 75 mg of clopidogrel until 30 days after OPCAB surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no clopidogrel)
Number of subjects: 29
Study: 15681270

Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (MT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Combination Therapy (CT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Interferential Therapy (IFT)
Number of subjects: 240
Study: 11943636

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (15 mg iron/day) for 3 months
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (15 mg iron/day) for 6 months
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (15 mg iron/week) for 6 months
Number of subjects: 270
Study: 10078179

Group type: EXPERIMENTAL
Intervention: Hospital-in-the-home (HIH) service
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 100
Study: 7742840

Group type: EXPERIMENTAL
Intervention: Aircast SportStirrup
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DonJoy RocketSoc
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonbraced control
Number of subjects: 25
Study: 8097332

Group type: EXPERIMENTAL
Intervention: Guanfacine (GUA) 0.5 mg IV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Guanfacine (GUA) 1.5 mg IV
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clonidine (CLON) 150 micrograms IV
Number of subjects: 18
Study: 3800343

Group type: EXPERIMENTAL
Intervention: 4 g mezlocillin every 6 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 g mezlocillin every 8 h
Number of subjects: 12
Study: 30138389

Group type: COMPARATOR
Intervention: Antithrombotic medications (including aspirin-dipyridamole plus clopidogrel, rivaroxaban plus aspirin, warfarin plus aspirin, warfarin plus aspirin and clopidogrel)
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Aspirin-dipyridamole plus clopidogrel
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Warfarin plus aspirin and clopidogrel
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Rivaroxaban plus aspirin
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Warfarin plus aspirin
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Dabigatran monotherapy
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Dabigatran plus aspirin
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Users of antithrombotic medication
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 3131270

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3131270
Study: 29897685

Group type: EXPERIMENTAL
Intervention: TCM based acupuncture with manual stimulation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 70
Study: 25893426

Group type: EXPERIMENTAL
Intervention: i.v. low‐dose endotoxin (lipopolysaccharide [LPS])
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: i.v. fat
Number of subjects: 16

Group type: COMPARATOR
Intervention: i.v. glycerol (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oral fat
Number of subjects: 16
Study: 24823927

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 20
Study: 21709087

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine with 200 ml milk containing 6.4 g fat (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dihydroartemisinin‐piperaquine with water (fasting patients, n = 15)
Number of subjects: 30
Study: 18843535

Group type: EXPERIMENTAL
Intervention: Preventive intervention for perinatal depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive intervention for aggressive disruptive behavior in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CACE and IV methods
Number of subjects: 0
Study: 16537848

Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12773121

Group type: EXPERIMENTAL
Intervention: Swallowed meal (1708 kJ mixed meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham-fed meal (1708 kJ mixed meal)
Number of subjects: 12
Study: 11111997

Group type: EXPERIMENTAL
Intervention: Celsior preservation solution (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) preservation solution (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both Celsior and UW preservation solutions
Number of subjects: 41
Study: 9639942

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (observational studies)
Number of subjects: 0
Study: 7825253

Group type: EXPERIMENTAL
Intervention: Thyroid disease without eye motility complaints (n = 90)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Thyroid patients with eye muscle involvement (diplopia, n = 47)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Patients without thyroid disease but with 'big eyes' (n = 51)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (n = 203)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Thyroid patients with eye muscle involvement
Number of subjects: 203

Group type: COMPARATOR
Intervention: Other groups (thyroid disease without eye motility complaints, patients without thyroid disease with 'big eyes')
Number of subjects: 203
Study: 3255485

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (10-20 ng/kg body weight/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard therapy (Control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol
Number of subjects: 12
Study: 30202030

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib with rifampicin (10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib with pyrazinamide (25 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard TB drugs alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib with TB drugs
Number of subjects: 0
Study: 26886017

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administered the same day as chemotherapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Pegfilgrastim administered the next day after chemotherapy
Number of subjects: 192
Study: 24128381

Group type: EXPERIMENTAL
Intervention: Smoking-cessation treatment (SCT) including weekly individual counseling, extended-release bupropion (300 mg/day), nicotine inhaler, and contingency management for smoking abstinence
Number of subjects: 267

Group type: COMPARATOR
Intervention: Continued smoking (Control)
Number of subjects: 267
Study: 22410862

Group type: EXPERIMENTAL
Intervention: Lymphatic massage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lymphatic massage + Compression sleeve
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no compression sleeve)
Number of subjects: 30
Study: 20484898

Group type: EXPERIMENTAL
Intervention: LMWH PS (n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: LMWH CTA (n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: No anticoagulation PS (n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: No anticoagulation CTA (n = 24)
Number of subjects: 96
Study: 19292165

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 48

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 48
Study: 15782318

Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide (iNO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo gas (nitrogen)
Number of subjects: 15
Study: 12424485

Group type: EXPERIMENTAL
Intervention: 1 g dipyrone in 10 ml saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (intravenous injection of 10 ml saline)
Number of subjects: 60
Study: 9495568

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (0.05 g/day) for six months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (0.05 g/day) + Medroxyprogesterone acetate (MPA; 10 mg/day, per orally for the last ten days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day, per orally)
Number of subjects: 66
Study: 2571307

Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neither glycopyrronium nor vecuronium
Number of subjects: 40
Study: 960166

Group type: EXPERIMENTAL
Intervention: Hypocarbic general anesthesia (PaCO2 less than 25 torr)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hypercarbic general anesthesia (PaCO2 greater than 60 torr)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative stroke incidence
Number of subjects: 100
Study: 30634037

Group type: EXPERIMENTAL
Intervention: MICS CABG
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sternotomy CABG
Number of subjects: 88
Study: 28792334

Group type: EXPERIMENTAL
Intervention: Written, spoken, and visual menus (meal-ordering systems)
Number of subjects: 10
Study: 26069175

Group type: EXPERIMENTAL
Intervention: Group A - Long arteriotomy on LAD with complete opening of LIMA and anastomosis along LAD course
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B - Small arteriotomy only in areas where the wall of the vessel was nearly normal with sequential (Jump) method for LIMA anastomosis
Number of subjects: 40
Study: 24417987

Group type: EXPERIMENTAL
Intervention: aranidipine 5-20 mg/d
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: retard-released felodipine 5-10 mg/d
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: aranidipine 20 mg/d
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: aranidipine
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: retard-released felodipine
Number of subjects: 315
Study: 21440891

Group type: EXPERIMENTAL
Intervention: SAFE or SORRY? programme
Number of subjects: 0
Study: 19487960

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (carboplatin and paclitaxel)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Single-agent therapy (gemcitabine or vinorelbine)
Number of subjects: 391
Study: 17302059

Group type: EXPERIMENTAL
Intervention: Percutem clamp fixation (PCCF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unilateral multifunctional external fixator (UMFEF)
Number of subjects: 200
Study: 15142327

Group type: EXPERIMENTAL
Intervention: Higher dosage group (18 daily sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower dosage group (9 daily sessions)
Number of subjects: 0
Study: 11298843

Group type: EXPERIMENTAL
Intervention: 3000 IU hCG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 225 IU recombinant FSH
Number of subjects: 10
Study: 9486672

Group type: EXPERIMENTAL
Intervention: Flurandrenolide tape (4 microg/cm2) applied once daily for up to 16 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diflorasone diacetate ointment (0.05%) applied twice daily
Number of subjects: 30
Study: 7799597

Group type: EXPERIMENTAL
Intervention: Thermovision examination in injured persons
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Autodermoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thermovision examination in control group
Number of subjects: 40
Study: 3059900

Group type: EXPERIMENTAL
Intervention: Cotton bract extract (CBE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 13
Study: 683658

Group type: EXPERIMENTAL
Intervention: Uterine exteriorization (eventrated group)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Uterine in situ (noneventrated group)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 386
Study: 30476517

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF treatment)
Number of subjects: 474
Study: 28399118

Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 19
Study: 25767124

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8-week Skype delivered)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 40
Study: 23773361

Group type: EXPERIMENTAL
Intervention: Pain that interfered at least moderately with daily living
Number of subjects: 699
Study: 22716281

Group type: EXPERIMENTAL
Intervention: Retinol intake
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Liver as a source of retinol intake
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: Carotenes, vitamin C, and vitamin E intake
Number of subjects: 1631
Study: 19616856

Group type: EXPERIMENTAL
Intervention: Cognitive training (10 weeks, twice weekly)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 16
Study: 17095635

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EX)
Number of subjects: 34
Study: 16298650

Group type: EXPERIMENTAL
Intervention: Daclizumab (DAC) induction
Number of subjects: 298

Group type: COMPARATOR
Intervention: No antibody induction (Control)
Number of subjects: 298
Study: 12548358

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 20

Group type: COMPARATOR
Intervention: clozapine
Number of subjects: 20
Study: 9662468

Group type: COMPARATOR
Intervention: Antithrombin concentrates
Number of subjects: 0
Study: 7658948

Group type: EXPERIMENTAL
Intervention: Concentric contractions at 90% of maximal concentric power
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eccentric contractions at 90% of maximal concentric power
Number of subjects: 20
Study: 2527545

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg once daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg once daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg day‐1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg day‐1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 853054

Group type: EXPERIMENTAL
Intervention: Aortic reconstructions with lumbar sympathectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aortic reconstructions without lumbar sympathectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Femoropopliteal bypass
Number of subjects: 80
Study: 31104905

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard Radiation Therapy (RT)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: EPIC bowel domain
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: PRO‐CTCAE
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: FACT
Number of subjects: 278
Study: 28596511

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg orally one hour before the operation (G1, G3)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control groups (G2, G4)
Number of subjects: 82
Study: 26073770

Group type: EXPERIMENTAL
Intervention: Web-assisted calprotectin-based treatment algorithm (IBD-live)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual practices
Number of subjects: 180
Study: 23842118

Group type: EXPERIMENTAL
Intervention: Real-time manikin compression feedback during simulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no real-time feedback)
Number of subjects: 30
Study: 21899207

Group type: EXPERIMENTAL
Intervention: Test product (Metacard MR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study: 19543683

Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with Toupet partial fundoplication
Number of subjects: 26
Study: 16677640

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day
Number of subjects: 93
Study: 15162251

Group type: EXPERIMENTAL
Intervention: Iron supplement of 47 mg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dietary plan rich in iron providing 26 mg per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Regular diet (control group)
Number of subjects: 42
Study: 10931747

Group type: EXPERIMENTAL
Intervention: rhGH for reconstitution (24 IU or 8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid formulation of rhGH (5, 10 or 15 mg per 1.5 ml)
Number of subjects: 0
Study: 9308928

Group type: EXPERIMENTAL
Intervention: Etanidazole combined with radiotherapy (2 g/m2, three times weekly for 17 doses)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Conventional radiotherapy alone (66 Gy in 33 fractions to 74 Gy in 37 fractions, 5 fractions per week)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Etanidazole combined with radiotherapy
Number of subjects: 374

Group type: COMPARATOR
Intervention: Conventional radiotherapy alone
Number of subjects: 374
Study: 8340985

Group type: EXPERIMENTAL
Intervention: Topical anesthetic cream, eutectic mixture of local anesthetics (EMLA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3451218

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29447784

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Standard of care (admission to intensive care and angiography after 3 days unless signs of acute ischemia or hemodynamic instability)
Number of subjects: 1006
Study: 26812786

Group type: EXPERIMENTAL
Intervention: Oral prednisone (tapered over 14 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intratympanic methylprednisolone (40 mg/mL, injected twice a week for 2 weeks)
Number of subjects: 42
Study: 24988909

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenges (n=101)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo lozenges (n=97)
Number of subjects: 198
Study: 22987687

Group type: EXPERIMENTAL
Intervention: Chloride channel mutations
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sodium channel mutations
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: DM2 mutations
Number of subjects: 91

Group type: COMPARATOR
Intervention: Historical normal controls
Number of subjects: 91
Study: 20360917

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rest periods during 40% of 1RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rest periods during 80% of 1RM
Number of subjects: 20
Study: 18822733

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate hydrogel (1 mL/cm2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline gauze (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate hydrogel
Number of subjects: 60